MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 528816 | Name: Ceftolozane sulfate
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Ceftolozane is a fifth-generation cephalosporin antibiotic with potent activity against Pseudomonas aeruginosa, including multidrug-resistant strains, and various Enterobacteriaceae. It exhibits bactericidal action by inhibiting penicillin-binding proteins (PBPs), disrupting bacterial cell wall synthesis. In vitro, ceftolozane shows MIC<sub>90</sub> values of 1–4 µg/mL against most P. aeruginosa strains, including some resistant to other β-lactams. When combined with the β-lactamase inhibitor tazobactam (as in ceftolozane/tazobactam), its spectrum extends to include many ESBL-producing E. coli and K. pneumoniae, with MIC<sub>90</sub> values often ≤2 µg/mL.

Chemical Structure

Ceftolozane sulfate
Ceftolozane sulfate
CAS#936111-69-2 (sulfate)

Theoretical Analysis

MedKoo Cat#: 528816

Name: Ceftolozane sulfate

CAS#: 936111-69-2 (sulfate)

Chemical Formula: C23H31N12O12S3

Exact Mass: 0.0000

Molecular Weight: 763.75

Elemental Analysis: C, 36.17; H, 4.09; N, 22.01; O, 25.14; S, 12.59

Price and Availability

Size Price Availability Quantity
5mg USD 1,950.00 2 Weeks
10mg USD 3,650.00 2 Weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
689293-68-3 (free base) 936111-69-2 (sulfate)
Synonym
FR-264205; FR264205; FR 264205; Ceftolozane sulfate;
IUPAC/Chemical Name
mono(5-amino-2-(((6R,7R)-7-((Z)-2-(5-amino-1,2,4-thiadiazol-3-yl)-2-(((2-carboxypropan-2-yl)oxy)imino)acetamido)-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl)methyl)-4-(3-(2-aminoethyl)ureido)-1-methyl-1H-pyrazol-2-ium) monosulfate
InChi Key
UJDQGRLTPBVSFN-TVNHLQOTSA-M
InChi Code
InChI=1S/C23H30N12O8S2.H2O4S/c1-23(2,20(40)41)43-31-11(15-30-21(26)45-32-15)16(36)29-12-17(37)35-13(19(38)39)9(8-44-18(12)35)6-34-7-10(14(25)33(34)3)28-22(42)27-5-4-24;1-5(2,3)4/h7,12,18,25H,4-6,8,24H2,1-3H3,(H7,26,27,28,29,30,32,36,38,39,40,41,42);(H2,1,2,3,4)/p-1/b31-11-;/t12-,18-;/m1./s1
SMILES Code
CN1[N+](CC(CS[C@]2([H])[C@@H]3NC(/C(C4=NSC(N)=N4)=N\OC(C)(C(O)=O)C)=O)=C(C(O)=O)N2C3=O)=CC(NC(NCCN)=O)=C1N.O=S([O-])([O-])=O
Appearance
Solid powder ( Stabilized with Arginine, 1:1 by w/w )
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 763.75 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Kaye KS, Pogue JM. Infections Caused by Resistant Gram-Negative Bacteria: Epidemiology and Management. Pharmacotherapy. 2015 Oct;35(10):949-62. doi: 10.1002/phar.1636. Review. PubMed PMID: 26497481. 2: Solomkin J, Hershberger E, Miller B, Popejoy M, Friedland I, Steenbergen J, Yoon M, Collins S, Yuan G, Barie PS, Eckmann C. Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI). Clin Infect Dis. 2015 May 15;60(10):1462-71. doi: 10.1093/cid/civ097. Epub 2015 Feb 10. PubMed PMID: 25670823; PubMed Central PMCID: PMC4412191. 3: Golan Y. Empiric therapy for hospital-acquired, Gram-negative complicated intra-abdominal infection and complicated urinary tract infections: a systematic literature review of current and emerging treatment options. BMC Infect Dis. 2015 Aug 5;15:313. doi: 10.1186/s12879-015-1054-1. Review. PubMed PMID: 26243291; PubMed Central PMCID: PMC4526420. 4: Cluck D, Lewis P, Stayer B, Spivey J, Moorman J. Ceftolozane-tazobactam: A new-generation cephalosporin. Am J Health Syst Pharm. 2015 Dec 15;72(24):2135-46. doi: 10.2146/ajhp150049. Review. PubMed PMID: 26637512. 5: Wagenlehner FM, Umeh O, Steenbergen J, Yuan G, Darouiche RO. Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI). Lancet. 2015 May 16;385(9981):1949-56. doi: 10.1016/S0140-6736(14)62220-0. Epub 2015 Apr 27. PubMed PMID: 25931244. 6: Cho JC, Fiorenza MA, Estrada SJ. Ceftolozane/Tazobactam: A Novel Cephalosporin/β-Lactamase Inhibitor Combination. Pharmacotherapy. 2015 Jul;35(7):701-15. doi: 10.1002/phar.1609. Epub 2015 Jul 1. Review. PubMed PMID: 26133315. 7: Liscio JL, Mahoney MV, Hirsch EB. Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. Int J Antimicrob Agents. 2015 Sep;46(3):266-71. doi: 10.1016/j.ijantimicag.2015.05.003. Epub 2015 Jun 14. Review. PubMed PMID: 26143591. 8: Kern WV. [New antibacterial agents on the market and in the pipeline]. Internist (Berl). 2015 Nov;56(11):1255-63. Review. German. PubMed PMID: 26475603. 9: Sucher AJ, Chahine EB, Cogan P, Fete M. Ceftolozane/Tazobactam: A New Cephalosporin and β-Lactamase Inhibitor Combination. Ann Pharmacother. 2015 Sep;49(9):1046-56. doi: 10.1177/1060028015593293. Epub 2015 Jul 9. Review. PubMed PMID: 26160970. 10: Gelfand MS, Cleveland KO. Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-Resistant Pseudomonas aeruginosa. Clin Infect Dis. 2015 Sep 1;61(5):853-5. doi: 10.1093/cid/civ411. Epub 2015 May 28. PubMed PMID: 26021991. 11: Bettiol E, Harbarth S. Development of new antibiotics: taking off finally? Swiss Med Wkly. 2015 Jul 31;145:w14167. doi: 10.4414/smw.2015.14167. eCollection 2015 Jul 31. PubMed PMID: 26230280. 12: Bush K. A resurgence of β-lactamase inhibitor combinations effective against multidrug-resistant Gram-negative pathogens. Int J Antimicrob Agents. 2015 Nov;46(5):483-93. doi: 10.1016/j.ijantimicag.2015.08.011. Epub 2015 Sep 25. Review. PubMed PMID: 26498989. 13: Karaiskos I, Giamarellou H. Multidrug-resistant and extensively drug-resistant Gram-negative pathogens: current and emerging therapeutic approaches. Expert Opin Pharmacother. 2014 Jul;15(10):1351-70. doi: 10.1517/14656566.2014.914172. Epub 2014 Apr 28. Review. PubMed PMID: 24766095; PubMed Central PMCID: PMC4819585. 14: van Duin D, Bonomo RA. Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations. Clin Infect Dis. 2016 Jul 15;63(2):234-41. doi: 10.1093/cid/ciw243. Epub 2016 Apr 20. PubMed PMID: 27098166; PubMed Central PMCID: PMC4928383. 15: Lee YR, McMahan D, McCall C, Perry GK. Complicated Intra-Abdominal Infections: The Old Antimicrobials and the New Players. Drugs. 2015 Dec;75(18):2097-117. doi: 10.1007/s40265-015-0506-7. Review. PubMed PMID: 26612473. 16: Berrazeg M, Jeannot K, Ntsogo Enguéné VY, Broutin I, Loeffert S, Fournier D, Plésiat P. Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins. Antimicrob Agents Chemother. 2015 Oct;59(10):6248-55. doi: 10.1128/AAC.00825-15. Epub 2015 Jul 27. PubMed PMID: 26248364; PubMed Central PMCID: PMC4576058. 17: Papp-Wallace KM, Bonomo RA. New β-Lactamase Inhibitors in the Clinic. Infect Dis Clin North Am. 2016 Jun;30(2):441-64. doi: 10.1016/j.idc.2016.02.007. Review. PubMed PMID: 27208767; PubMed Central PMCID: PMC4980828. 18: Zhanel GG, Chung P, Adam H, Zelenitsky S, Denisuik A, Schweizer F, Lagacé-Wiens PR, Rubinstein E, Gin AS, Walkty A, Hoban DJ, Lynch JP 3rd, Karlowsky JA. Ceftolozane/tazobactam: a novel cephalosporin/β-lactamase inhibitor combination with activity against multidrug-resistant gram-negative bacilli. Drugs. 2014 Jan;74(1):31-51. doi: 10.1007/s40265-013-0168-2. Review. PubMed PMID: 24352909. 19: Chandorkar G, Xiao A, Mouksassi MS, Hershberger E, Krishna G. Population pharmacokinetics of ceftolozane/tazobactam in healthy volunteers, subjects with varying degrees of renal function and patients with bacterial infections. J Clin Pharmacol. 2015 Feb;55(2):230-9. doi: 10.1002/jcph.395. Epub 2014 Nov 14. PubMed PMID: 25196976; PubMed Central PMCID: PMC4303958. 20: Armstrong ES, Farrell DJ, Palchak M, Steenbergen JN. In Vitro Activity of Ceftolozane-Tazobactam against Anaerobic Organisms Identified during the ASPECT-cIAI Study. Antimicrob Agents Chemother. 2015 Nov 9;60(1):666-8. doi: 10.1128/AAC.01964-15. PubMed PMID: 26552971; PubMed Central PMCID: PMC4704157.